Jianyang Zhao

Title: Innovations of Jianyang Zhao in Anti-Angiogenesis

Introduction

Jianyang Zhao is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of anti-angiogenesis therapies. His work focuses on creating innovative solutions to combat diseases related to vascular growth factors.

Latest Patents

Jianyang Zhao holds a patent for an anti-angiogenesis fusion protein. This invention combines a chimeric vascular endothelial cell growth factor (VEGF) receptor or a fragment thereof with a multimerizing component. The fusion protein exhibits superior binding capacity with human VEGF and placental growth factor (PIGF). It boasts improved stability, a prolonged half-life, and the ability to form multivalent interactions with VEGF. This innovation has potential applications in treating VEGF-related diseases and inhibiting tumor growth.

Career Highlights

Jianyang Zhao is associated with Genor Biopharma Co., Ltd., where he continues to advance his research and development efforts. His work has positioned him as a key figure in the biopharmaceutical industry, contributing to the understanding and treatment of complex diseases.

Collaborations

Some of his notable coworkers include Joe Zhou and Jiuru Sun, who collaborate with him on various projects within the company.

Conclusion

Jianyang Zhao's innovative work in anti-angiogenesis fusion proteins represents a significant advancement in the field of biopharmaceuticals. His contributions have the potential to impact the treatment of various diseases, showcasing the importance of innovation in medical research.